EBioMedicine (Mar 2022)
SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women
- Youri Lee,
- Gabrielle Grubbs,
- Sabrina C. Ramelli,
- Andrea R. Levine,
- Allison Bathula,
- Kapil Saharia,
- Madeleine Purcell,
- Shreya Singireddy,
- Colleen L. Dugan,
- Lindsey Kirchoff,
- Allison Lankford,
- Sarah Cipriano,
- Ryan A. Curto,
- Jocelyn Wu,
- Katherine Raja,
- Emily Kelley,
- Daniel Herr,
- Kevin M. Vannella,
- Supriya Ravichandran,
- Juanjie Tang,
- Anthony Harris,
- Mohammad Sajadi,
- Daniel S. Chertow,
- Alison Grazioli,
- Surender Khurana
Affiliations
- Youri Lee
- Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD 20871, USA
- Gabrielle Grubbs
- Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD 20871, USA
- Sabrina C. Ramelli
- Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
- Andrea R. Levine
- Division of Pulmonary and Critical Care, Department of Internal Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
- Allison Bathula
- Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD, USA
- Kapil Saharia
- Division of Infectious Disease, Department of Internal Medicine, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD USA
- Madeleine Purcell
- University of Maryland School of Medicine, Baltimore, MD USA
- Shreya Singireddy
- University of Maryland School of Medicine, Baltimore, MD USA
- Colleen L. Dugan
- University of Maryland Medical Center, Baltimore, MD USA
- Lindsey Kirchoff
- University of Maryland Medical Center, Baltimore, MD USA
- Allison Lankford
- Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, MD, USA
- Sarah Cipriano
- University of Maryland Medical Center, Baltimore, MD USA
- Ryan A. Curto
- University of Maryland School of Medicine, Baltimore, MD USA
- Jocelyn Wu
- University of Maryland School of Medicine, Baltimore, MD USA
- Katherine Raja
- University of Maryland School of Medicine, Baltimore, MD USA
- Emily Kelley
- University of Maryland Medical Center, Baltimore, MD USA
- Daniel Herr
- Department of Medicine, Program in Trauma, University of Maryland School of Medicine, Baltimore, MD, USA
- Kevin M. Vannella
- Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- Supriya Ravichandran
- Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD 20871, USA
- Juanjie Tang
- Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD 20871, USA
- Anthony Harris
- Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD USA
- Mohammad Sajadi
- Department of Medicine, Baltimore VA Medical Center, Baltimore, MD 21201, USA
- Daniel S. Chertow
- Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- Alison Grazioli
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD USA
- Surender Khurana
- Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD 20871, USA; Corresponding author.
- Journal volume & issue
-
Vol. 77
p. 103940
Abstract
Summary: Background: Limited knowledge exists in post-partum women regarding durability of SARS-CoV-2 vaccine-induced antibody responses and their neutralising ability against SARS-CoV-2 variants of concern (VOC). Methods: We elucidated longitudinal mRNA vaccination-induced antibody profiles of 13 post-partum and 13 non-post-partum women (control). Findings: The antibody neutralisation titres against SARS-CoV-2 WA-1 strain were comparable between post-partum and non-post-partum women and these levels were sustained up to four months post-second vaccination in both groups. However, neutralisation titers declined against several VOCs, including Beta and Delta. Higher antibody binding was observed against SARS-CoV-2 receptor-binding domain (RBD) mutants with key VOC amino acids when tested with post-second vaccination plasma from post-partum women compared with controls. Importantly, post-vaccination plasma antibody affinity against VOCs RBDs was significantly higher in post-partum women compared with controls. Interpretation: This study demonstrates that there is a differential vaccination-induced immune responses in post-partum women compared with non-post-partum women, which could help inform future vaccination strategies for these groups.
